Paliperidone palmitate for schizophrenia (Q24202846)

https://api.crossref.org/works/10.1002%2F14651858.CD008296.PUB2

Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008296.PUB2

Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008296.PUB2

A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008296.PUB2

A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008296.PUB2

Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008296.PUB2

A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008296.PUB2

Are the long-acting intramuscular formulations of risperidone or paliperidone palmitate associated with post-injection delirium/sedation syndrome? An assessment of safety databases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008296.PUB2

Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008296.PUB2

A rating scale for drug-induced akathisia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008296.PUB2

Statistics notes. Trials randomised in clusters

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008296.PUB2

Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008296.PUB2

The unit of analysis error in studies about physicians' patient care behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008296.PUB2

Issues in the meta-analysis of cluster randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008296.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008296.PUB2

Meta-analyses involving cross-over trials: methodological issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008296.PUB2

Inconsistency in risperidone long-acting injection steady-state plasma levels when switching from deltoid to gluteal administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008296.PUB2

Second-generation antipsychotic long-acting injections: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008296.PUB2

Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008296.PUB2

Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008296.PUB2

Depot risperidone for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008296.PUB2

Intramuscular paliperidone palmitate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008296.PUB2

Risperidone versus typical antipsychotic medication for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008296.PUB2

Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate: results from a clinical trial with a 52-week open-label extension (OLE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008296.PUB2

What does the PANSS mean?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008296.PUB2

Clinical implications of Brief Psychiatric Rating Scale scores

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008296.PUB2

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008296.PUB2

Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008296.PUB2

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008296.PUB2

Oral paliperidone for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008296.PUB2

Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008296.PUB2

A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008296.PUB2

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD008296.PUB2

1 reference

7 January 2021

Reliability, validity and ability to detect change of the clinician-rated Personal and Social Performance scale in patients with acute symptoms of schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008296.PUB2

7 January 2021

The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008296.PUB2

7 January 2021

Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008296.PUB2

7 January 2021